VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	19.18	EPS (ttm)	10.51	Insider Own	0.20%	Shs Outstand	259.37M	Perf Week	0.54%
Market Cap	51.87B	Forward P/E	15.68	EPS next Y	12.86	Insider Trans	-15.31%	Shs Float	258.52M	Perf Month	-0.02%
Income	2.76B	PEG	1.96	EPS next Q	3.00	Inst Own	93.60%	Short Float	1.58%	Perf Quarter	-7.62%
Sales	6.41B	P/S	8.09	EPS this Y	128.00%	Inst Trans	0.38%	Short Ratio	1.83	Perf Half Y	-12.00%
Book/sh	34.62	P/B	5.82	EPS next Y	6.87%	ROA	23.90%	Target Price	260.73	Perf Year	-27.85%
Cash/sh	26.91	P/C	7.49	EPS next 5Y	9.80%	ROE	32.60%	52W Range	185.32 - 283.45	Perf YTD	-14.71%
Dividend	-	P/FCF	17.33	EPS past 5Y	45.30%	ROI	26.40%	52W High	-29.95%	Beta	0.64
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	43.20%	Gross Margin	88.10%	52W Low	7.14%	ATR	4.08
Employees	3400	Current Ratio	4.40	Sales Q/Q	13.80%	Oper. Margin	44.50%	RSI (14)	47.85	Volatility	2.28% 1.85%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	9.00%	Profit Margin	42.30%	Rel Volume	1.08	Prev Close	201.58
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Jul 29 AMC	Payout	0.00%	Avg Volume	2.24M	Price	198.55
Recom	1.80	SMA20	-0.40%	SMA50	-1.13%	SMA200	-7.72%	Volume	2,097,231	Change	-1.50%

Jul-20-21

Downgrade

SVB Leerink

Mkt Perform → Underperform

$170

Jul-19-21

Resumed

Wolfe Research

Outperform

$252

Jul-01-21

Initiated

Raymond James

Mkt Perform

Jun-11-21

Downgrade

Daiwa Securities

Outperform → Neutral

$210

Feb-23-21

Upgrade

Robert W. Baird

Neutral → Outperform

$220 → $252

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$315 → $275

Dec-30-20

Initiated

Daiwa Securities

Outperform

$250

Nov-30-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$247 → $267

Nov-20-20

Initiated

Bernstein

Outperform

$225

Oct-28-20

Initiated

UBS

Buy

$287

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$295 → $315

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$300

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$270 → $295

Apr-28-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$250 → $260

Mar-04-20

Initiated

Barclays

Overweight

$271

Jan-31-20

Downgrade

Robert W. Baird

Outperform → Neutral

$210 → $230

Nov-19-19

Upgrade

Guggenheim

Neutral → Buy

$252

Nov-12-19

Initiated

SunTrust

Buy

$235

Oct-17-19

Resumed

BofA/Merrill

Buy

$220

Sep-03-19

Upgrade

Goldman

Neutral → Buy

$226 → $254

Aug-02-21 07:00AM	15 Words From Vertex's CEO That Signal Major Growth Ahead Motley Fool
05:52AM	3 Beaten-Down Growth Stocks to Buy Right Now Motley Fool
Jul-31-21 08:37AM	Better Buy: Vertex vs. CRISPR Motley Fool
Jul-30-21 12:31PM	15 Most Valuable Biotech Companies in the World Insider Monkey
11:16AM	Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up Zacks
10:31AM	CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y Zacks
10:02AM	Vertex Pharmaceuticals Incorporated (VRTX) Q2 2021 Earnings Call Transcript Motley Fool
Jul-29-21 05:25PM	Vertex Pharmaceuticals (VRTX) Q2 Earnings and Revenues Surpass Estimates Zacks
04:01PM	Vertex Reports Second-Quarter 2021 Financial Results Business Wire
Jul-28-21 08:00AM	Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis Business Wire
05:51AM	5 Stocks I Own That I Want to Add to When the Stock Market Crashes Motley Fool
Jul-26-21 12:03PM	Vertex (VRTX) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-24-21 05:33AM	Is CRISPR Therapeutics a Millionaire-Maker Stock? Motley Fool
Jul-23-21 12:33PM	CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards? Zacks
10:20AM	3 Things About CRISPR Therapeutics That Smart Investors Know Motley Fool
Jul-22-21 03:03PM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
11:14AM	3 Things About Vertex Pharmaceuticals That Smart Investors Know Motley Fool
Jul-21-21 09:31AM	Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX Zacks
07:18AM	2 Top Biotech Stocks to Buy Right Now Motley Fool
Jul-20-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
02:06PM	10 Best Stocks to Buy According to Billionaire Steve Cohen Insider Monkey
07:40AM	Vertex (VRTX) Initiates Phase II Study on Pain Candidate Zacks
06:43AM	Have $2,000? 2 All-Weather Stocks to Buy This Month Motley Fool
Jul-19-21 11:51PM	Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Relatively low PE may be Offering Investors an Opportunity Simply Wall St.
08:00AM	Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain Business Wire
06:06AM	3 Nasdaq 100 Stocks to Buy Hand Over Fist in July Motley Fool
Jul-16-21 04:01PM	Vertex to Announce Second-Quarter 2021 Financial Results on July 29 Business Wire
11:40AM	VRTX vs. PRTA: Which Stock Should Value Investors Buy Now? Zacks
Jul-15-21 08:30AM	If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now Zacks
Jul-14-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
05:51AM	5 Stocks That Can Make You Rich Motley Fool
Jul-13-21 12:45PM	3 Reasons Growth Investors Will Love Vertex (VRTX) Zacks
Jul-07-21 08:04AM	Eloxx Pharma Sees Data Readout From First Four Arms Of Cystic Fibrosis Study By End Of 2021 Benzinga
Jul-06-21 06:30AM	Can These 2 Beaten-Down Biotechs Rebound? Cathie Wood Thinks So. Motley Fool
Jul-05-21 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
Jul-04-21 05:51AM	Chart a Path to Financial Independence With These Unstoppable Stocks Motley Fool
Jul-03-21 07:01AM	What Are the Odds That Vertex Strikes a Big Acquisition Deal? Motley Fool
Jul-01-21 06:09AM	1 Biotech Stock Investors Should Really Have on Their Radars Right Now Motley Fool
06:05AM	Could Vertex Pharmaceuticals Be a Prime Acquisition Target? Motley Fool
Jun-30-21 01:42PM	15 Best Medical Stocks to Invest In Insider Monkey
06:42AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals Zacks
Jun-28-21 05:50PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
09:26AM	Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients Business Wire
Jun-25-21 01:44PM	Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis Business Wire
10:43AM	Vertex Pharmaceuticals Announces $1.5B Stock Repurchase Program SmarterAnalyst
Jun-24-21 01:50PM	Should You Still Invest in Vertex Pharmaceuticals (VRTX) Despite its Poor Q1 Results? Insider Monkey
05:55AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List Too Motley Fool
Jun-21-21 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
06:06AM	5 Growth Stocks I've Bought Over the Past 2 Months Motley Fool
Jun-18-21 03:50PM	Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation CNW Group
03:37PM	Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation Business Wire
Jun-17-21 06:00AM	Cathie Wood Bought This Stock for a Bargain. Should You Follow? Motley Fool
Jun-16-21 02:34PM	Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS Zacks
06:43AM	Vertex in a Vortex, But Recent Failures Can Be Turned Around TipRanks
04:49AM	Why Are Analysts Still Bullish About Vertex Pharmaceuticals After VX-864 Update? TipRanks
Jun-15-21 08:35PM	2 Stocks That Are Flirting With a Bottom; Analysts Say Buy TipRanks
06:55AM	Can Vertex Pharmaceuticals Recover From Its Latest Setback? Motley Fool
05:40AM	Is It Too Late to Buy Vertex Pharmaceuticals Stock? Motley Fool
04:37AM	CRISPR on the Cutting Edge of Gene Editing Technology TipRanks
Jun-14-21 05:50PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
03:45PM	Hedge Funds Have Never Been This Bullish On Vertex Pharmaceuticals Incorporated (VRTX) Insider Monkey
10:50AM	CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data Zacks
09:38AM	Company News for Jun 14, 2021 Zacks
Jun-11-21 04:15PM	Biotech Finds Market Love at Last as Meme Traders, FDA Converge Bloomberg -10.96%
04:12PM	Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock Investor's Business Daily
01:42PM	Dow Slips, Small Caps Lead Upside, Nasdaq Holds Gain; These Biotech Stocks Make Notable Moves Investor's Business Daily
11:35AM	VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower InvestorPlace
10:42AM	Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate Zacks
10:33AM	Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials Benzinga
09:24AM	Why Vertex Pharmaceuticals Stock Is Getting Hammered Today Motley Fool
08:55AM	Biogen Gains, Vertex Pharmaceuticals Drops, and the Stock Market Keeps Rising Barrons.com
08:46AM	Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial data MarketWatch
06:45AM	Wait a Few Days to Trade Vertex So You Don't Get Your Face Ripped Off TheStreet.com
06:23AM	Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles Benzinga
05:52AM	Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner Motley Fool
04:36AM	Premarket Movers Friday: Vertex Pharma, AMC, Dave & Buster's TheStreet.com
03:05AM	Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at European Hematology Association Annual Meeting Business Wire
02:43AM	Vertex Pharmaceuticals Seen as Buying Opportunity as Stock Plunges TheStreet.com
Jun-10-21 06:21PM	Vertex Pharma Stumbles In Rare-Disease Effort, Buoying Rival Arrowhead Pharma Investor's Business Daily
04:03PM	Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency Business Wire
02:23PM	Vertex Halts Further Study of AATD Drug TheStreet.com
12:12PM	Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children Zacks
06:06AM	Ditch Dogecoin: These Stocks Are Screaming Buys in June Motley Fool
Jun-09-21 02:37PM	Vertex Pharmaceuticals Nabs Key FDA Approval in Cystic Fibrosis Motley Fool
11:04AM	CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Business Wire
08:46AM	Vertex Pharma's Trikafta Triplet Therapy Wins FDA Approval For Expanded Use In Children 6-11 Years With Cystic Fibrosis Benzinga
Jun-07-21 05:45PM	Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know Zacks
Jun-04-21 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
Jun-03-21 10:20AM	Battle of the $54 Billion Assets: Buy This, Not Dogecoin Motley Fool
05:51AM	3 Value Stocks That'll Make You Richer in June (and Beyond) Motley Fool
Jun-02-21 09:03AM	3 Biotech Stocks With Huge Catalysts in June Motley Fool
May-31-21 06:01AM	The Best Biotech Stocks to Buy With $500 Motley Fool
May-29-21 08:51AM	3 Stocks to Hold for the Next 20 Years Motley Fool
May-26-21 06:10AM	Don't Wait For a Market Crash: These 2 Top Stocks Are On Sale Motley Fool
06:05AM	4 Unstoppable Healthcare Stocks to Buy on the Dip Motley Fool
May-22-21 06:25AM	Is Vertex Pharmaceuticals a Buy? Motley Fool
05:51AM	A Stock Market Crash May Be Near: 3 Stocks to Buy Hand Over Fist When It Happens Motley Fool
May-19-21 08:26AM	Does Vertex Pharmaceuticals (NASDAQ:VRTX) Deserve A Spot On Your Watchlist? Simply Wall St.
06:00AM	3 Biotech Stocks You'll Be Glad You Bought at These Prices Motley Fool
May-18-21 06:43AM	Concert Pharma Sells VX-561-Related Milestones To Vertex For $32M Benzinga

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bhatia Sangeeta N.	Director	Jun 02	Sale	209.69	559	117,216	5,191	Jun 04 04:03 PM
Arbuckle Stuart A	EVP, Chief Comm & Ops Officer	May 17	Sale	216.41	109	23,589	41,103	May 19 04:04 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 17	Sale	216.36	79	17,093	33,589	May 19 04:02 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 17	Sale	216.34	112	24,230	34,108	May 19 04:10 PM
Sachdev Amit	EVP, Chief Patient Officer	May 17	Sale	216.35	45	9,736	40,133	May 19 04:08 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 03	Sale	218.43	960	209,691	34,108	May 05 09:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Option Exercise	86.52	3,884	336,044	44,017	Apr 29 04:03 PM
Sachdev Amit	EVP, Chief Patient Officer	Apr 27	Sale	216.06	3,884	839,193	40,133	Apr 29 04:03 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 05	Sale	214.14	1,686	361,046	35,834	Apr 07 04:04 PM
Liu Joy	SVP, General Counsel	Mar 05	Sale	209.69	5,141	1,078,018	8,253	Mar 08 04:10 PM
Silva Paul M	SVP & Chief Accounting Officer	Mar 01	Sale	211.45	2,782	588,255	9,884	Mar 02 04:07 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 25	Sale	213.47	1,080	230,551	14,884	Feb 26 04:23 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 25	Sale	213.42	3,586	765,307	40,133	Feb 26 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 25	Sale	213.38	3,028	646,125	30,837	Feb 26 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 25	Sale	213.54	3,634	775,989	41,103	Feb 26 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 25	Sale	213.39	3,028	646,139	33,589	Feb 26 04:03 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 18	Sale	211.83	4,295	909,828	16,828	Feb 19 04:21 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 18	Sale	211.83	9,264	1,962,366	46,665	Feb 19 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 18	Sale	211.83	7,825	1,657,556	36,281	Feb 19 04:18 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 18	Sale	211.82	7,825	1,657,481	47,635	Feb 19 04:08 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 18	Sale	211.83	7,825	1,657,590	39,033	Feb 19 04:05 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 11	Sale	210.55	4,460	939,068	63,542	Feb 16 04:20 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 11	Sale	210.57	1,498	315,437	23,863	Feb 16 04:24 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 11	Sale	210.56	1,686	355,012	38,864	Feb 16 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 11	Sale	210.56	4,318	909,179	50,346	Feb 16 04:15 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 11	Sale	210.55	5,156	1,085,593	61,700	Feb 16 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 11	Sale	210.54	5,283	1,112,274	53,098	Feb 16 04:02 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Option Exercise	86.52	1,930	166,984	59,157	Feb 09 07:44 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Sale	215.00	1,930	414,950	57,227	Feb 09 07:44 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Option Exercise	86.52	1,554	134,452	71,511	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Option Exercise	86.52	400	34,608	57,627	Feb 05 04:52 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Sale	213.74	1,554	332,146	69,957	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Sale	216.56	400	86,624	57,227	Feb 05 04:52 PM
Sachdev Amit	EVP, Chief Patient Officer	Nov 16	Sale	223.53	42	9,388	35,103	Nov 18 04:16 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 16	Sale	223.53	91	20,341	26,838	Nov 18 04:12 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 16	Sale	223.64	7	1,565	35,179	Nov 18 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 16	Sale	223.47	38	8,492	28,902	Nov 18 04:10 PM
SACHS BRUCE I	Director	Nov 10	Buy	217.36	15,000	3,260,465	26,210	Nov 12 08:18 AM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Option Exercise	86.52	2,330	201,592	29,168	Nov 06 04:09 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Sale	217.74	2,330	507,329	26,838	Nov 06 04:09 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Option Exercise	86.52	1,553	134,366	36,732	Nov 05 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Sale	211.92	1,553	329,115	35,179	Nov 05 04:16 PM
Bhatia Sangeeta N.	Director	Oct 05	Option Exercise	126.68	8,729	1,105,790	14,424	Oct 07 04:11 PM
Bhatia Sangeeta N.	Director	Oct 05	Sale	266.79	10,516	2,805,518	3,908	Oct 07 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Option Exercise	155.57	1,223	190,262	30,125	Aug 10 04:13 PM
Kewalramani Reshma	CEO & President	Aug 06	Option Exercise	179.68	2,073	372,482	28,699	Aug 10 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Option Exercise	155.57	1,223	190,262	28,061	Aug 10 04:22 PM
Silva Paul M	SVP & Controller	Aug 06	Option Exercise	169.39	1,078	182,598	16,010	Aug 10 04:24 PM
Silva Paul M	SVP & Controller	Aug 06	Sale	271.17	1,078	292,319	14,932	Aug 10 04:24 PM
Kewalramani Reshma	CEO & President	Aug 06	Sale	271.20	2,073	562,205	26,626	Aug 10 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Sale	271.19	1,223	331,663	28,902	Aug 10 04:13 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Sale	271.20	1,223	331,672	26,838	Aug 10 04:22 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Option Exercise	86.52	1,553	134,366	36,732	Aug 05 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Option Exercise	86.52	2,330	201,592	29,168	Aug 05 04:20 PM
Silva Paul M	SVP & Controller	Aug 03	Option Exercise	86.52	809	69,995	15,741	Aug 05 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Option Exercise	86.52	2,330	201,592	31,232	Aug 05 04:14 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Option Exercise	86.52	1,941	167,935	37,044	Aug 05 04:51 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Sale	278.28	1,941	540,137	35,103	Aug 05 04:51 PM
Silva Paul M	SVP & Controller	Aug 03	Sale	278.30	809	225,142	14,932	Aug 05 04:24 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Sale	278.28	2,330	648,402	26,838	Aug 05 04:20 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Sale	278.39	1,553	432,337	35,179	Aug 05 04:17 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Sale	278.24	2,330	648,290	28,902	Aug 05 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience